ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för repotrectinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2024-03-03

CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.

Terrones M, Deben C, Rodrigues-Fortes F, Schepers A, de Beeck KO, Van Camp G, Vandeweyer G.

J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12967-024-04988-0

Bibliografisk träff 2024-02-19

Repotrectinib (Augtyro) for non-small cell lung cancer.

Författaruppgift saknas

Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2024.1696g

Bibliografisk träff 2024-02-01

Repotrectinib: First Approval.

Dhillon S.

Drugs · review; journal article · DOI 10.1007/s40265-023-01990-6

Bibliografisk träff 2024-01-11

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.

Balasundaram A, Doss GPC.

Front Mol Biosci · research-article; journal article · DOI 10.3389/fmolb.2023.1306046

Bibliografisk träff 2024-01-01

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.

Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC, TRIDENT-1 Investigators.

N Engl J Med · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa2302299

Bibliografisk träff 2023-12-15

ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.

Gao L, Ai X, Lu S.

Lung Cancer · research support, non-u.s. gov't; journal article; case reports · DOI 10.1016/j.lungcan.2023.107443

Bibliografisk träff 2023-12-07

Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases.

Cipri S, Fabozzi F, Del Baldo G, Milano GM, Boccuto L, Carai A, Mastronuzzi A.

Front Oncol · review-article; review; journal article · DOI 10.3389/fonc.2023.1235794

Bibliografisk träff 2023-11-16

Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer.

Metro G, Gariazzo E, Costabile S, Baglivo S, Roila F, Colamartini F, Palumbo B, Chiarini P, Gori S, Conti A, Marcomigni L, Bellezza G, Lunardi G.

Oncol Ther · journal article; case-report · DOI 10.1007/s40487-023-00251-6

Bibliografisk träff 2023-11-08

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.

Xiang S, Lu X.

Acta Pharm Sin B · review-article; review; journal article · DOI 10.1016/j.apsb.2023.11.010

Bibliografisk träff 2023-11-01

The promising impact of Bemcentinib and Repotrectinib on sleep impairment in Alzheimer's disease.

Ariaei A, Ramezani F.

J Biomol Struct Dyn · journal article · DOI 10.1080/07391102.2023.2276876

Bibliografisk träff 2023-07-26

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report.

Pizzutilo EG, Agostara AG, Roazzi L, Romanò R, Motta V, Lauricella C, Marrapese G, Cerea G, Signorelli D, Veronese SM, Giannetta LG, Sartore-Bianchi A, Siena S.

JTO Clin Res Rep · journal article; case reports; case-report · DOI 10.1016/j.jtocrr.2023.100555

Bibliografisk träff 2023-05-01

Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors.

Chen MF, Yang SR, Shia J, Girshman J, Punn S, Wilhelm C, Kris MG, Cocco E, Drilon A, Raj N.

JCO Precis Oncol · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural; case-report · DOI 10.1200/po.22.00697

Bibliografisk träff 2022-10-06

Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors.

Doi Y, Tagaya H, Noge A, Semba K.

Target Oncol · research support, non-u.s. gov't; journal article · DOI 10.1007/s11523-022-00919-5

Bibliografisk träff 2022-05-11

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.

Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S.

Cancer Sci · research-article; journal article · DOI 10.1111/cas.15354

Bibliografisk träff 2022-03-16

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.

Harada G, Drilon A.

Cancer Genet · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1016/j.cancergen.2022.03.002

Bibliografisk träff 2022-02-26

Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation.

Fan Y, Zhang Y, Liu Y, Jiang H, Zhou Y, Tang C, Fan W.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2022.128646

Bibliografisk träff 2021-10-21

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.

Li W, Sparidans RW, Lebre MC, Beijnen JH, Schinkel AH.

Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics13111761

Bibliografisk träff 2021-10-08

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.

Murray BW, Rogers E, Zhai D, Deng W, Chen X, Sprengeler PA, Zhang X, Graber A, Reich SH, Stopatschinskaja S, Solomon B, Besse B, Drilon A.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1535-7163.mct-21-0632

Bibliografisk träff 2021-09-04

Translational Strategies for Repotrectinib in Neuroblastoma.

O'Donohue TJ, Ibáñez G, Coutinho DF, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long M, Roberts SS, Kung AL, Dela Cruz FS.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-21-0126

Bibliografisk träff 2021-07-12

Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.

Liu Z, Yu P, Dong L, Wang W, Duan S, Wang B, Gong X, Ye L, Wang H, Tian J.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c00712

Bibliografisk träff 2020-04-08

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.

Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1078-0432.ccr-19-2777

Bibliografisk träff 2020-04-01

Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.

Li W, Perpinioti N, Schinkel AH, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2020.122098

Bibliografisk träff 2019-12-18

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.

Cervantes-Madrid D, Szydzik J, Lind DE, Borenäs M, Bemark M, Cui J, Palmer RH, Hallberg B.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-019-55060-7

Bibliografisk träff 2018-09-19

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.

Yan W, Lakkaniga NR, Carlomagno F, Santoro M, McDonald NQ, Lv F, Gunaganti N, Frett B, Li HY.

J Med Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.8b01092

Bibliografisk träff 2018-08-09

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT.

Cancer Discov · research support, non-u.s. gov't; journal article · DOI 10.1158/2159-8290.cd-18-0484

Gå till forskningen.

Publikationer i urvalet

CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.

Repotrectinib (Augtyro) for non-small cell lung cancer.

Repotrectinib: First Approval.

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.

Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer.

ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.

Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases.

Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer.

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.

The promising impact of Bemcentinib and Repotrectinib on sleep impairment in Alzheimer's disease.

Repotrectinib Overcomes F2004V Resistance Mutation in <i>ROS1</i>-Rearranged NSCLC: A Case Report.

Response to Repotrectinib After Development of <i>NTRK</i> Resistance Mutations on First- and Second-Generation TRK Inhibitors.

Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors.

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.

Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation.

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.

Translational Strategies for Repotrectinib in Neuroblastoma.

Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.

Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.